Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer. Issue 6 (3rd October 2013)

• Record Type: Journal Article
• Authors: Yoshida, Takeichi; Kato, Jun; Inoue, Izumi; Yoshimura, Noriko; Deguchi, Hisanobu; Mukoubayashi, Chizu; Oka, Masashi; Watanabe, Mika; Enomoto, Shotaro; Niwa, Toru; Maekita, Takao; Iguchi, Mikitaka; Tamai, Hideyuki; Utsunomiya, Hirotoshi; Yamamichi, Nobutake; Fujishiro, Mitsuhiro; Iwane, Masataka; Takeshita, Tatsuya; Ushijima, Toshikazu; Ichinose, Masao
• Is Part Of: International journal of cancer. Volume 134:Issue 6(2014:Mar. 15)
• Page Start: 1445
• Page End: 1457
• Publication Date: 2013-10-03
• Subjects: Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.28470
• Languages: English
• ISSNs: 0020-7136

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Our study investigated the relationship between gastric cancer development and activity of <italic>Helicobacter pylori</italic>‐associated chronic gastritis or the resulting chronic atrophic gastritis (CAG). A cohort of 4, 655 healthy asymptomatic subjects, in whom serum pepsinogen (PG) and <italic>H. pylori</italic> antibody titer had been measured to assess the activity and stage of <italic>H. pylori</italic>‐associated chronic gastritis, was followed for up to 16 years, and cancer development was investigated. In subjects with a serologically diagnosed healthy stomach (<italic>H. pylori</italic>‐negative/CAG‐negative), cancer incidence rate was low, at 16/100, 000 person‐years. With the establishment of <italic>H. pylori</italic> infection and progression of chronic gastritis, significant stepwise cancer risk elevations were seen from CAG‐free subjects (<italic>H. pylori</italic>‐positive/CAG‐negative) [hazard ratio (HR) = 8.9, 95% confidence interval (CI) = 2.7–54.7] to subjects with CAG (<italic>H. pylori</italic>‐positive/CAG‐positive) (HR = 17.7, 95% CI = 5.4–108.6) and finally to subjects with metaplastic gastritis (<italic>H. pylori</italic>‐negative/CAG‐positive) (HR = 69.7, 95% CI = 13.6–502.9). In <italic>H. pylori</italic>‐infected CAG‐free subjects, significantly elevated cancer risk was observed in the subgroup with active inflammation‐based high PG II level or potent immune response‐based high <italic>H. pylori</italic> antibody titer; the former was associated with a particularly high risk of diffuse‐type cancer, and both subgroups showed high cancer incidence rates of around 250/100, 000 person‐years, comparable to that in subjects with CAG. No such risk elevation was observed in <italic>H. pylori</italic>‐infected subjects with CAG. These results clearly indicate that gastric cancer develops mainly from the gastritis‐atrophy‐metaplasia‐cancer sequence and partly from active inflammation‐based direct carcinogenesis, and that serum levels of PG and <italic>H. pylori</italic> antibody titer provide indices of cancer development in <italic>H. pylori</italic>‐infected subjects.</p> </abstract>